Our Products and Research & Development Pipeline
| Development stage | Research/ Pre-clinical |
Phase I | Phase II | Phase III | Marketed | Comments |
|---|---|---|---|---|---|---|
| Marketed products: | ||||||
| Quinvaxem® | Fully liquid vaccine for protection against five childhood diseases. | |||||
| Hepavax-Gene® | Recombinant hepatitis B vaccine. | |||||
| MoRu-Viraten® | Vaccine for protection against measles and rubella (all age groups). | |||||
| Epaxal® | Aluminum-free hepatitis A vaccine. | |||||
| Epaxal® Junior | Low dosage unique aluminum-free hepatitis A vaccine (0.25 ml). | |||||
| Vivotif® | Oral typhoid vaccine. | |||||
| Dukoral® | Internationally licensed oral vaccine against cholera (and ETEC). | |||||
| Inflexal® V | Virosomal adjuvanted influenza vaccine (all age groups). | |||||
| Vaccines in development: | ||||||
| Flavimum® | Yellow fever vaccine. | |||||
| Influenza seasonal | Pandemic (or seasonal) influenza vaccine.1 | |||||
| Tuberculosis | Recombinant AdVac®-based tuberculosis vaccine.2 | |||||
| Malaria | Recombinant AdVac®-based malaria vaccine.3 | |||||
| Ebola & Marburg | Recombinant AdVac®-based Ebola and Marburg vaccine.3 | |||||
| HIV | Recombinant HIV vaccine.4 | |||||
| Human antibodies in development: | ||||||
| Rabies antibody combination | Fast track | Two human antibodies for post-exposure treatment of rabies.5 | ||||
| Influenza antibodies H1 and H5 | Neutralizing antibody cross reactive against H1N1 and H5N1. | |||||
| Other: | ||||||
| Factor V L/C | Blood coagulation Factor V L/C. | |||||
- 1
- Developed by sanofi pasteur using PER.C6®.
- 2
- Partnered with Aeras.
- 3
- Partnered with NIAID/NIH.
- 4
- Partnered with Harvard.
- 5
- Partnered with sanofi pasteur.